Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,041.7
-29.5 (-0.96%)

 

  • STI Straits Times Index
    3,041.7
    -29.5 (-0.96%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,527.9
    -20.6 (-1.33%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,099.1
    -821.6 (-3.30%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,614.0
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    30,323.3
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,076.3
    -56.9 (-0.93%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,423.4M
  • Value: 1,459.2M
  • Rise: 78
  • Fall: 304
  • Unch: 373

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.065-0.008
Sembcorp Marine0.082-0.002
Medi Lifestyle0.033-0.001
Singtel2.440+0.010
CapLand IntCom T2.000-
YZJ Shipbldg SGD1.440-0.040
Intl Cement0.031-0.002
Jiutian Chemical0.077-0.005
VCPlus0.027+0.001
CapitaLandInvest2.950-

World Indices

World Indices
Name Last Change
Nasdaq 14,713.9 -330.1
HSI 24,099.1
HSCEI 8,638.5
Jakarta 6,076.3
Nikkei 225 30,500.0
SSE Comp 3,614.0
Shanghai A 3,787.7
Shanghai B 273.1
KOSPI 3,130.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

KOTRA KOTRA INDUSTRIES BHD
Quotes 15 Minutes Delayed. Updated at 20 Sep 2021 16:42
Last (MYR): 2.800 Change: +0.020 High: 2.800 Remarks:
Change (%): +0.72 Low: 2.700
Open 2.750 Yesterday's Close 2.780
Buy Price 2.760 Sell Price 2.800
Buy Volume ('00) 14 Sell Volume ('00) 8
Cumulative Volume ('00) 738 Cumulative Value 200,603
Click to show Stock Prices chart

Key Statistics

EPS (MYR) a 0.16483 Trailing EPS (MYR) e 0.16483 NAV (MYR) b 1.3950
PE a 16.987 Trailing PE f 16.988 Price / NAV b 2.0072
Dividend (MYR) d - Cash In Hand (MYR) g 0.1075 Issued & Paid-up Shares c 147,974,483
Dividend Yield (%) d - Price / Cash In Hand g 26.047 Treasury Shares h -
Beta - 75 Daysi -0.662 R-Squared - 75 Days(%)i 1.04 Market Cap (M) 414.329
Beta - 500 Daysi 0.392 R-Squared - 500 Days (%)i 1.71 Enterprise Value (M) 364.581
Piotroski F Score 5 Exchange Code 0002 Par Value ( MYR ) n.a.
52 Weeks Volatility (%) 28.97 6-Month VWAP 2.921 Free Float (%) 19.0
Shariah Compliant Stocks Yes
Sector & Industry Health Technology - Pharmaceuticals: Major
Index Components BM HEALTH CARE
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 19 Aug 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 19 Aug 2021.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference KOTRA Bursa 414.329 16.987 16.988 2.0072 -
Industry PHARMACEUTICALS Bursa 741.528 25.845 25.946 2.4758 2.156
Pharmaceuticals: Major Bursa 716.636 - - 0.6602 0.664
Index BM HEALTH CARE Bursa 7,441.135 7.766 5.829 2.9418 2.137
Local Peer IGBB Bursa 1,702.507 184.109 - 0.4800 -
Local Peer BSTEAD Bursa 1,155.383 - - 0.3710 -
Local Peer PHARMA Bursa 1,080.716 39.323 33.824 3.0187 2.664
Local Peer NOVA Bursa 273.260 21.011 18.080 3.0518 1.663
Local Peer BIOHLDG Bursa 266.963 - - 1.4151 -
Local Peer SUNZEN Bursa 123.296 - - 1.3022 -
Global Peer JOHNSON & JOHNSON NYSE 433,701.080 29.475 24.410 6.2331 2.416
Global Peer PFIZER INC NYSE 246,077.624 25.590 18.603 3.5133 3.461
Global Peer ELI LILLY AND COMPANY NYSE 220,109.288 35.538 36.258 34.1552 1.286
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 203,225.382 25.027 22.595 3.7605 2.309
Global Peer ABBVIE INC NYSE 190,378.301 41.786 28.893 15.1466 4.488
Global Peer MERCK & CO INC NYSE 181,448.602 25.675 32.570 5.4499 3.458
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 179,755.310 27.896 25.250 17.1931 1.327
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 172,139.326 53.861 45.648 10.9811 2.089
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 136,237.564 - - 3.7013 3.031
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 122,252.873 8.709 17.654 1.6302 2.764
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), REPLIGEN CORP (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), CUREVAC NV (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), SINOPHARM (HKEx), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REMEGEN-B (HKEx), ALLAKOS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SH PHARMA (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), CMS (HKEx), AKESO-B (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BAIYUNSHAN PH (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), INNOCARE-B (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), CARSGEN-B (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), NEKTAR THERAPEUTICS (NASDAQ), CHINARES PHARMA (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), SIMCERE PHARMA (HKEx), IGM BIOSCIENCES INC (NASDAQ), ERASCA INC (NASDAQ), EVEREST MED-B (HKEx), TRAD CHI MED (HKEx), ADC THERAPEUTICS SA (NYSE), ATEA PHARMACEUTICALS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CSTONE PHARMA-B (HKEx), HENLIUS (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), SSY GROUP (HKEx), ZYMEWORKS INC (NYSE), OCUMENSION-B (HKEx), NURIX THERAPEUTICS INC (NASDAQ), HEPALINK (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GENERATION BIO CO (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), KRONOS BIO INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ICOSAVAX INC (NASDAQ), UNITED LAB (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH-B (HKEx), PHATHOM PHARMACEUTICALS INC (NASDAQ), TONGRENTANGCM (HKEx), KINNATE BIOPHARMA INC (NASDAQ), GH RESEARCH PLC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), SCICLONE PHARMA (HKEx), ANTENGENE-B (HKEx), Kimia Farma Tbk. (IDX), SUTRO BIOPHARMA INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CKLIFE SCIENCES (HKEx), BEYONDSPRING INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), SHINEWAY PHARM (HKEx), PETIQ INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), ZHAOKE OPHTH-B (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), AC IMMUNE SA (NASDAQ), CLENE INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), RELMADA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), 89BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), PROVENTION BIO INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ESSA PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), RACE ONCOLOGY LTD (ASX), APPLIED THERAPEUTICS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CYBIN INC (NYSE American), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM-B (HKEx), DURECT CORP (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), XOMA CORP (NASDAQ), DAWNRAYS PHARMA (HKEx), OBSEVA SA (NASDAQ), INOZYME PHARMA INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), ANNOVIS BIO INC (NYSE American), MUSTANG BIO INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), HARROW HEALTH INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), KALEIDO BIOSCIENCES INC (NASDAQ), IMMUNIC INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), FUSEN PHARM (HKEx), OVID THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), ALZAMEND NEURO INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), TRICIDA INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), IP (SET), RENEO PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CH BIOTECH SER (HKEx), TYME TECHNOLOGIES INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), GENPREX INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ZHONGZHIPHARM (HKEx), LANNETT CO INC (NYSE), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), IX Biopharma (SGX), RECCE PHARMACEUTICALS LTD (ASX), EYENOVIA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), Merck Tbk. (IDX), LYRA THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), GALECTO INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), CHARMACY PHAR (HKEx), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), SANAI HEALTH GP (HKEx), OCUPHIRE PHARMA INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), GRAYBUG VISION INC (NASDAQ), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), ABVC BIOPHARMA INC (NASDAQ), NC HEALTHCARE (HKEx), VIRPAX PHARMA INC (NASDAQ), Hyphens Pharma (SGX), INVION LTD (ASX), BRICKELL BIOTECH INC (NASDAQ), RENOVORX INC (NASDAQ), MANNATECH INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), MODERN CHI MED (HKEx), EXOPHARM LTD (ASX), NEP INTERLONG (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), PHARMAXIS (ASX), VALLON PHARMACEUTICALS INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), SEQLL INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), PURAPHARM (HKEx), AGEX THERAPEUTICS INC (NYSE American), TELIGENT INC NEW (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), DERMATA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), PALLA PHARMA LTD (ASX), EXTRAWELL PHAR (HKEx), JCT (SET), NLS PHARMACEUTICS LTD (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.030
-1.06 %
10 Days --0.080
-2.78 %
20 Days -+0.540
+23.89 %
Medium Term Return 3 Months -+0.250
+9.80 %
6 Months -+0.280
+11.11 %
1 Year 0.065-0.290
-7.28 %
Long Term Return 2 Years 0.154+0.970
+61.42 %
3 Years 0.214+1.100
+77.29 %
5 Years 0.254+1.770
+196.50 %
Annualised Return Annualised --
+24.28 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 2.250 - 3.560 Change From 1 Year Low +0.550 % Change From 1 Year Low (%) +24.44
Change From 1 Year High -0.760 % Change From 1 Year High (%) -21.35
2 Years Range 1.600 - 4.450 Change From 2 Years Low +1.200 % Change From 2 Years Low (%) +75.00
Change From 2 Years High -1.650 % Change From 2 Years High (%) -37.08
5 Years Range 1.030 - 4.450 Change From 5 Years Low +1.770 % Change From 5 Years Low (%) +171.84
Change From 5 Years High -1.650 % Change From 5 Years High (%) -37.08
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Kotra Industries Bhd. The Group's principal activities are the manufacturing and sale of pharmaceutical and healthcare products. Other activities include provision of management services and investment holding. Operations are carried out in Malaysia.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Jun 2019 Part 1(2.16 MB)
Annual Report 2018 Jun 2018 Part 1(2.39 MB)
Part 2(0.46 MB)
Part 3(0.06 MB)
Annual Report 2017 Jun 2017 Part 1(1.40 MB)
Annual Report 2016 Jun 2016 Part 1(1.80 MB)
Annual Report 2015 Jun 2015 Part 1(1.67 MB)
Annual Report 2014 Jun 2014 Part 1(1.09 MB)
Annual Report 2013 Jun 2013 Part 1(1.13 MB)
Annual Report 2012 Jun 2012 Part 1(2.70 MB)
Part 2(1.58 MB)
Annual Report 2011 Jun 2011 Part 1(2.33 MB)
Annual Report 2010 Jun 2010 Part 1(1.31 MB)
Annual Report 2009 Jun 2009 Part 1(0.95 MB)
Part 2(0.08 MB)
Annual Report 2008 Jun 2008 Part 1(0.71 MB)
Annual Report 2007 Jun 2007 Part 1(0.46 MB)
Annual Report 2006 Jun 2006 Part 1(1.31 MB)
Part 2(2.22 MB)
Annual Report 2005 Jun 2005 Part 1(0.75 MB)
Annual Report 2004 Jun 2004 Part 1(0.94 MB)
Annual Report 2003 Jun 2003 Part 1(0.63 MB)
Annual Report 2002 Jun 2002 Part 1(0.34 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
20 Sep 2021 2.750 2.800 2.700 2.800 73,800 2.7182
17 Sep 2021 2.780 2.830 2.780 2.780 22,100 2.7850
15 Sep 2021 2.720 2.770 2.710 2.770 51,000 2.7381
14 Sep 2021 2.820 2.820 2.710 2.770 96,600 2.7525
13 Sep 2021 2.900 2.900 2.800 2.830 68,900 2.8496
10 Sep 2021 2.850 2.880 2.820 2.830 81,600 2.8400
09 Sep 2021 2.850 2.900 2.820 2.890 207,100 2.8454
08 Sep 2021 2.930 3.000 2.840 2.930 144,900 2.9028
07 Sep 2021 2.880 3.070 2.880 2.940 344,900 2.9791
06 Sep 2021 2.900 2.900 2.820 2.880 143,500 2.8605
03 Sep 2021 2.950 2.960 2.850 2.900 256,900 2.8803
02 Sep 2021 3.330 3.440 2.950 3.020 1,207,800 3.1804
01 Sep 2021 2.740 3.180 2.700 3.180 1,525,600 3.0934
30 Aug 2021 2.450 2.550 2.450 2.450 31,400 2.4932
27 Aug 2021 2.320 2.450 2.300 2.450 32,900 2.3509
26 Aug 2021 2.410 2.410 2.410 2.410 300 2.4100
25 Aug 2021 2.360 2.360 2.360 2.360 - -
24 Aug 2021 2.270 2.360 2.270 2.360 900 2.3500
23 Aug 2021 2.260 2.260 2.260 2.260 - -
20 Aug 2021 2.260 2.260 2.260 2.260 - -
19 Aug 2021 2.260 2.260 2.260 2.260 10,000 2.2600
18 Aug 2021 2.260 2.260 2.260 2.260 1,500 2.2600
Summary
Current 2 Weeks
(06 Sep 2021 to 20 Sep 2021)
2.900 3.070 2.700 2.800 1,234,400 -
Previous 2 Weeks
(20 Aug 2021 to 03 Sep 2021)
2.260 3.070 2.260 2.900 3,055,800 -
4 Weeks from
(22 Jul 2021 to 19 Aug 2021)
2.350 3.070 2.300 2.260 94,900 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.